Showing results (11-20 of 800) with videos related to

Sort By:
Pageof 80
Molecular Cancer Therapeutics|December 6, 2008
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Leukemia Research|April 12, 2003
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemiaSrdan Verstovsek, Scott Lunin, Hagop Kantarjian, et al.
Leukemia & Lymphoma|June 20, 2007
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring SystemMiloslav Beran, Sijin Wen, Yu Shen, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|March 22, 2003
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AMLElihu Estey, Francis Giles, Jorge Cortes, et al.
Cancer|May 26, 2004
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phaseJorge Cortes, Susan O'Brien, Alfonso Quintas, et al.
The Oncologist|September 5, 2006
Advances in the therapy of chronic idiopathic myelofibrosisCecilia Arana-Yi, Alfonso Quintás-Cardama, Francis Giles, et al.
Haematologica|August 6, 2002
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromesGuillermo Garcia-Manero, Stefan Faderl, Francis Giles, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
Cancer|October 30, 2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseJorge Medina, Hagop Kantarjian, Moshe Talpaz, et al.
Pageof 80